Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR008
- Development stage
- Preclinical
- Lead developer
- Xiyuan Anjian Pharmaceutical
01
Overview
BR008 is an investigational drug candidate initially developed by Xiyuan Anjian Medicine (Shanghai) for the treatment of nervous system diseases, with a primary focus on neuralgia. As of March 2025, its highest reported development status is preclinical. The specific mechanism of action, molecular target(s), and modality have not been publicly disclosed. There are no available details regarding its chemical structure or pharmacological class. No evidence suggests that BR008 is related to the NRG-BR008/HERO clinical trial in breast cancer; these refer to different entities.
Beyond the preview
Go deeper on BR008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR008.